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Objective To determine the effects on the vaginal microbiota of
an oral probiotic preparation administered from early pregnancy.
Design Randomised, double blind, placebo-controlled trial.
Setting Four maternity units in the UK.
Population Women aged 16 years or older recruited at 9–
14 weeks’ gestation.
Methods Participants were randomly allocated to receive oral
capsules of probiotic containing Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14 each at 2.5 9 109 colony-forming units
(CFUs) or placebo once daily from recruitment until the end of
pregnancy.
Main outcome measure Rates of bacterial vaginosis (BV, defined
as Nugent score ≥7) at 18–20 weeks’ gestation compared by
logistic regression adjusted for possible confounders.
Results The primary analysis included 78% (238/304) of
participants who initially consented (probiotic group 123, placebo
group 115). Of these participants, 95% (227/238) reported an
intake of 93% or more of the required number of capsules. The
rates of BV did not differ between groups at 18–20 weeks’
gestation (15% (19/123) in the probiotic group vs. 9% (10/115) in
the placebo group, adjusted odds ratio 1.82, 95% confidence
interval 0.64–5.19). There were also no differences between the
groups in the proportion of women colonised with the probiotic
strains, Escherichia coli, Group B streptococci or other vaginal
microbiota. There were no differences in the alpha diversity or
composition of the bacterial communities between or within the
probiotic and placebo groups at 9–14 and 18–20 weeks’ gestation.
Conclusions Oral probiotics taken from early pregnancy did not
modify the vaginal microbiota.
Keywords Bacterial vaginosis, Lactobacillus reuteri, Lactobacillus
rhamnosus, probiotic.
Tweetable abstract The oral probiotic preparation used in this
study does not prevent BV in pregnant women.
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Introduction
Bacterial vaginosis (BV), in which the normally dominant
lactobacilli of the vagina are replaced with anaerobic bacte-
ria, is associated with adverse pregnancy outcomes
*Joint first authors and contributed equally to this paper.
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Randomised controlled trial
including preterm birth (PTB).1–4 Antibiotics are effective
in eradicating BV during pregnancy5 and are recommended
for use in symptomatic pregnant women.6 The
consequences of antibiotic use during pregnancy have been
poorly studied,7 but there are concerns that antibiotic-
related changes in the vaginal microbiota8 are associated
with short- and long-term morbidity in infancy and later
years.9
Probiotics might be a safe and effective alternative to
antibiotics in restoring the imbalance of the vaginal micro-
biota found in BV. Probiotics are defined as ‘live micro-
organisms that confer a health benefit on the host when
administered in adequate amounts’.10 Limited evidence
suggests that they have several beneficial roles including
the ability to displace and kill pathogens, and modulate the
body’s immune response.11,12 Lactobacilli, primarily the
strains that produce higher levels of hydrogen peroxide,
appear to protect against BV13–15 but the importance of
hydrogen peroxide in this is unclear.16
Evidence in non-pregnant women suggests that oral pro-
biotics can colonise the vagina, restore its microbiota in
the presence of microbial imbalance, and eradicate or
reduce the incidence of urogenital infections.17–21 Several
commercial probiotic products are marketed for the
restoration and maintenance of a ‘healthy vaginal micro-
biota’ in both non-pregnant and pregnant women22,23 but
evidence of colonisation or benefit in pregnant women is
lacking.
We therefore performed a randomised trial of a com-
mercially available probiotic preparation in pregnant
women to assess its biological effects on the vaginal micro-
biota. The constituents of the preparation have been shown
to colonise the vagina in some non-pregnant women. We
hypothesised that the probiotic preparation containing Lac-
tobacillus spp. taken orally from early pregnancy (9–14
completed weeks) would colonise the vagina and reduce
the prevalence of BV. The probiotic preparation selected
has been shown to be safe when taken during preg-
nancy.14,15
Methods
A pragmatic randomised, double-blind, placebo-controlled
trial with microbiome analysis was carried out to determine
the biological effects of oral probiotics on the vaginal
microbiota and the feasibility of conducting a full-scale
trial of oral probiotic supplementation of women from
early pregnancy to delivery in preventing PTB. The study
received ethics approval from the UK National Research
Ethics Committee (15/LO/1549) and was registered on
ClinicalTrials.gov (NCT02692820). We followed CONSORT
guidelines24 to produce this report, and analysis was
conducted using an analysis plan agreed in advance with
the independent trial steering and data monitoring com-
mittee.
Participants
Women in early pregnancy were recruited from the mater-
nity departments of four East London hospitals during
their routine dating ultrasound scan appointment. All par-
ticipants provided written informed consent. Eligible
women were aged 16 years and above at consent and
between 9 and 14 weeks’ gestation as confirmed by the dat-
ing ultrasound scan. We excluded those unable to provide
written informed consent or who had a poor understand-
ing of verbal or written English. There were no other exclu-
sion criteria. Maternal demographic, medical and obstetric
history, and antibiotic and probiotic use data were col-
lected.
Interventions
The treatment group received oral probiotic capsules con-
taining 2.5 billion CFUs each of L. rhamnosus GR-1and L.
reuteri RC-14, while the placebo group received identical
capsules containing excipients alone (Chr. Hansen, Hør-
sholm, Denmark). The contents of both capsules are stable
at room temperature, and enough capsules were provided
to each participant at the time of enrolment to last until
42 weeks’ gestation. We cultured the lactobacilli from a
sample of the probiotic capsules before the start of the trial
to ensure they were viable and could be detected by our
culture techniques. Participants were instructed to take one
capsule daily until delivery and self-report compliance at
each study visit.25
Outcomes
Our primary outcome was the rate of BV at 18–20 weeks’
gestation, measured using the Nugent score (Nugent
score ≥7 shows presence of BV). Secondary outcomes were
vaginal colonisation rates at 18–20 weeks’ gestation of the
probiotic or other Lactobacillus spp., two common neonatal
pathogens (Escherichia coli and Group B streptococcus),
and the composition of the vaginal microbiota.
Study plan
Research midwives approached potentially eligible women
attending their routine dating ultrasound scan appoint-
ment. After confirming eligibility, informed consent was
obtained and baseline data recorded. A double-headed
vaginal swab was collected, and the research midwife dis-
pensed randomised packs of placebo or probiotic capsules.
Vaginal swab samples were obtained again at two time
points, 18–20 weeks’ and 34–36 weeks’ gestation, during
scheduled routine antenatal appointments. At each visit,
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participants were asked to report on antibiotic use and any
side effects from the intervention.
Sample size
A sample size of 366 was calculated to estimate the propor-
tion of recruited women who would complete the study.
Based on studies carried out on non-pregnant women trea-
ted orally with the same lactobacillus strain,20 this sample
size would allow us to detect with at least 80% power a
decrease in BV of at least 50%, assuming a baseline risk of
25%, following treatment with the Lactobacillus spp. inter-
vention.26
Randomisation
The random allocation sequence was generated based on
permuted blocks of random block sizes of four, six, and
eight, stratified by participating site and without adaptive
or minimisation strategies. Allocation was done on a 1:1
ratio. The sequence was given to a trial support company,
Sharp Clinical Services (SCS, Crickhowell, Wales), which
labelled and packaged the probiotic and placebo capsules
into identical tamper-proof boxes for the study. Only the
trial statistician and SCS were aware of the allocation
sequence.
Blinding and allocation concealment
The probiotic and placebo capsules, made of hard
hypromellose, were provided in identical plastic tubes by
the manufacturer and shipped directly to SCS. The alloca-
tion sequence was used to label the tubes with details of
the products’ expiry date, storage instructions, and direc-
tions for use. These were then packaged into tamper-proof
boxes. Participants, investigators, and analysing microbiolo-
gists were blinded to the study grouping.
Microbiology methodology
The double-headed swab was separated in the laboratory.
One swab was used to prepare a glass slide for Gram stain,
and the other was extracted into 3 ml of Brain Heart Infu-
sion broth (Unipath Ltd, Basingstoke, UK) containing 10%
glycerol and 0.005% cysteine hydrochloride. The swab used
to prepare the slide was stored at 70 °C and later used in
the vaginal microbiota DNA profiling.
Gram-stained glass slides prepared from the swabs were
examined by microscopy and scored between 0 and 10
based on bacterial morphotypes according to the Nugent
method.27 Stored samples were thawed and diluted through
a series of 10-fold dilutions in saline before being inocu-
lated onto a range of selective and non-selective culture
media (Unipath). These included Mann Rogosa Sharpe
(MRS) agar incubated for 48 h at 35 °C in 10% CO2,
Columbia blood agar incubated aerobically at 37 °C for
48 h, Fastidious Anaerobe agar with 5% horse blood and
kanamycin incubated anaerobically at 36 °C for 48 to 72 h,
Sabouraud’s agar plates incubated micro-aerophilically at
36 °C for 24–48 h, and MacConkey agar incubated aerobi-
cally at 37 °C for 48 h. Colony counts from serial dilutions
allowed an estimate of the numbers of different species and
strains identified. These cultures allowed identification of
Lactobacillus spp., Enterobacteriaceae, and Group B
streptococci. Isolates were identified using matrix-assisted
laser desorption/ionisation-time of flight (MALDI-TOF)
analysis.28
Vaginal bacterial community profiling
DNA was extracted from thawed samples by means of the
GenElute Bacterial Genomic DNA kit (Sigma-Aldrich,
Poole, UK), modified to optimise lysis of Gram-positive
bacteria, following the manufacturer’s instructions. From
each DNA extract, variable regions V1 and V2 of the 16S
rRNA gene were amplified by PCR using fusion primers
incorporating template specific primers 27F-YM
(AGAGTTTGATYMTGGCTCAG) and 338R-R (TGCTG
CCTCCCGTAGRAGT) and MiSeq adapters and barcodes
to achieve a double indexing system. Amplicons were puri-
fied and normalised using the SequalPrep Normalization
Plate Kit (ThermoFisher Scientific, Dartford, UK). Sequenc-
ing was performed at the Barts and The London Genome
Centre using an Illumina MiSeq instrument, with a 2 9
250 flow cell for paired-end sequencing. Sequence reactions
were spiked with 10% 12.5 pM PhiX DNA. Reads were fil-
tered by quality score using DADA229 to remove sequences
with an expected error over 2 bp. The forward and reverse
sequences were truncated at 250 and 200 bp, respectively.
The filtered sequences were analysed using the mothur
pipeline according to the SOP available at https://
www.mothur.org/wiki/MiSeq_SOP. Sequences were clus-
tered into operational taxonomic units (OTUs) at a
sequence dissimilarity distance of 0.015 using an average
neighbour algorithm and then classified using a Na€ıve
Bayesian classifier implemented in mothur with the Human
Oral Microbiome Database release 14.51 reference dataset.
The alpha diversity of the samples was estimated by calcu-
lating the Inverse Simpson index and compared between
groups by the Wilcoxon test. A dissimilarity theta-YC
matrix between the samples was constructed with the same
subsampling approach averaging over 1000 replicas. The
beta diversity between subject groups was then compared
using the AMOVA test.
Statistical analysis
We used descriptive analysis to report baseline characteris-
tics of trial participants by allocated group. Continuous
variables were reported as means and standard deviations,
and ordinal/categorical variables were reported as absolute
and relative frequencies. To assess the microbiological
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effects of probiotics on vaginal microbiota, we compared
the proportion of women with BV and the proportion of
women with vaginal colonisation of the intervention spe-
cies at 18–20 weeks’ gestation between the groups. Nugent
score was dichotomised as BV (score ≥7) and no BV (score
0–6).
We estimated treatment effect using binary logistic
regression model adjusting for possible confounders, as this
approach has known benefits including enhancement of
power.30 A covariate was considered a confounding factor
if the difference between adjusted and unadjusted model
coefficients for the intervention variables varied by more
than 10%. In such cases, the odds ratio (OR) was shown
along with the list of confounders used for adjustment.
Otherwise, we reported the model without adjusting for
confounders. Mean Nugent score and its 95% confidence
interval (CI) were also plotted by group from baseline to
34–36 weeks’ gestation to compare evolution of the marker
during pregnancy.
All analysis was carried out using STATA software ver-
sion 14.31
Patient and public involvement
Patient representatives provided input into the design, pro-
tocol development, and conduct of the study. Prior to this
trial, a qualitative study was conducted to obtain input
from women.32 The available core outcome set for PTB33
had an influence on data collected. We are planning to dis-
seminate findings in the form of a newsletter and PPI feed-
back session, following primary publication of these results
through our patient network.34
Results
We screened 1301 pregnant women between 3 May and 1
July 2016 for their eligibility to participate in the study. A
total of 997 women were excluded from the trial either
because they did not meet the inclusion criteria (270/1301)
or they declined to participate. Those who declined to par-
ticipate did so mostly because of an unwillingness to take
the study intervention (138/727) and not being interested
in research study participation (250/727). After exclusions,
304 women were recruited and randomised to the probiotic
(152 women) and placebo (152 women) groups. At 18–
20 weeks’ gestation, 123 women remained in the probiotic
group and 115 in the placebo group. Complete data for
primary analysis were therefore available for 238 (78%)
randomised women (Figure 1).
There were no differences in characteristics of partici-
pants between the two groups at baseline (Table 1). In a
random sample of probiotic capsules tested for Lactobacilli,
the mean count was 2 9 109 for L. rhamnosus GR-1 and
1 9 109 for L. reuteri RC-14. No other bacteria were
detected. Self-reported compliance to the intervention at
18–20 weeks’ was 93% (114/123) in the probiotic group
and 98% (113/115) in the placebo group. No serious
adverse events related to the study interventions were
reported.
At 18–20 weeks’ gestation, the rate of BV in the probi-
otic group was 15% (19/123) compared with 9% (10/115)
in the placebo group. There were no differences between
the groups in the rates of vaginal colonisation with
L. rhamnosus GR-1 (5%, 6/123 and 5%, 6/115), E. coli
(23.6%, 29/123 and 25.2%, 29/115) or Group B strepto-
cocci (4%, 5/123 and 8%, 9/115). Vaginal colonisation with
L. reuteri RC-14 was not detected in either group
(Table 1). After adjusting for Nugent score at baseline,
there were no differences between the groups in the odds
of BV (adjusted OR 1.82, 95% CI 0.64–5.19; P = 0.26).
Of the women who provided a swab sample at 18–
20 weeks’ gestation, vaginal samples were available in 70%
(167/238) of women at 34–36 weeks’ gestation (72% (83/
115) in the placebo group and 68% (84/123) in the probi-
otic group. The mean Nugent scores at 9–14, 18–20, and
34–36 weeks’ gestation in the probiotic group were 1.74
(95% CI 1.08–2.40), 1.54 (95% CI 0.87–2.20), and 1.74
(95% CI 1.10–2.38), respectively. In the placebo group, the
mean Nugent scores at the same time points were 1.17
(95% CI 0.67–1.67), 0.86 (95% CI 0.37–1.34), and 1.33
(95% CI 0.82–1.83), respectively (Figure 2). The rates of
BV in the groups over the same period were 17% (14/84),
13% (11/84), and 13% (11/84) in the probiotic group and
6% (5/83), at all three time points in the placebo group.
Although the secondary outcomes did not differ between
the two groups, this trial was not powered to assess these
adequately. There was one miscarriage in the placebo group
and three in the probiotic group, all occurring between 9–
14 weeks’ and 18–20 weeks’ gestation. There were nine and
eight PTBs in the placebo and probiotic groups, respec-
tively, giving PTB rates of 8.2% and 6.7%; these rates are
consistent with the 7.7% PTB rate reported for England
and Wales in 2015.35 In each group, the mean duration of
pregnancy was 39 weeks, and in those who delivered pre-
term, 36 weeks.
Participants (n = 152) who attended at all time-points
were selected for the microbiome analysis. PCR amplifica-
tion at baseline failed in two participants in each group,
and the 18–20 weeks’ gestation swabs from three partici-
pants were unavailable, leaving 147 participants who pro-
vided 299 samples (75 in each group at baseline, and 74
and 75 in the probiotic and placebo groups, respectively, at
18–20 weeks’). The 16S rRNA genes were successfully
amplified and sequenced from these, and 6714 sequence
reads were sub-sampled from each sample. The composi-
tion of the vaginal community was as expected, with sub-
sets dominated by Lactobacillus crispatus, Lactobacillus
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iners or Lactobacillus jensenii. A further group was charac-
terised by a diverse community, which included anaerobic
species and Gardnerella vaginalis (Figure 3).
There were no significant differences (Wilcoxon) in
alpha diversity (Inverse Simpson index) or composition
(AMOVA) of the bacterial community in the probiotic and
placebo groups at either 9–14 or 18–20 weeks’ gestation
(Figure 3). The stability of the microbiota within subjects
assessed by determining the theta-YC distance between the
baseline and 18–20 weeks’ gestation samples was not signif-
icantly different between the probiotic and placebo groups
(Wilcoxon).
Discussion
The aim of this trail was to compare the effects on the
vaginal microbiota of oral probiotic capsules containing
L. rhamnosus GR-1 and L. reuteri RC-14 versus placebo
taken orally from early pregnancy until delivery. The bio-
logical effects were measured by Nugent scoring and cul-
ture of vaginal samples collected at three time points
during pregnancy.
Main findings
The oral administration of L. rhamnosus GR-1 and L. reu-
teri RC-14 daily from early pregnancy did not affect the
prevalence of BV or common neonatal pathogens, or alter
the composition of the vaginal microbiota at 18–20 weeks’
gestation. Previous observational studies and small-scale
randomised controlled trials in non-pregnant populations
have suggested that oral administration of probiotics can
alter the vaginal microbiota in a significant number of
women where microbial imbalance exists.18–21 It is on this
basis that several commercial probiotic products are mar-
keted for the restoration and maintenance of a healthy
vaginal microbiota in both non-pregnant and pregnant
women.19,20 Our findings have not shown any effect on the
vaginal microbiota with the probiotic preparation used in
this trial.
The microbiota at human colonisation sites is resistant
to perturbation; this resistance is referred to as colonisation
resistance.36,37 It is likely that stable colonisation with
desirable probiotic strains will require a reduction in
colonisation resistance. Little is known about modulation
of vaginal colonisation resistance at the present time.
Strengths and weakness of the study
This study was a large and pragmatic multicenter, ran-
domised trial carried out in pregnant women to assess the
effect of probiotic supplementation on the vaginal micro-
biota. We recruited women in early pregnancy and the
time to our primary endpoint was long enough to observe
an effect of the intervention on the vaginal micro-
biota.15,19,20,38 The large sample size and participant
Assessed for eligibility (n = 1301)
Recruited and randomised (n = 304)
Excluded (n = 997)
-Did not meet inclusion criteria (n = 270)
-Declined to participate (n = 727) 
Lost to follow up (n = 29)
-Post consent withdrawal (n = 7 )
-Did not attend appointment visit  (n = 22)
Placebo group (n = 152) Probiotic group (n = 152)
Lost to follow up (n = 37)
-Post consent withdrawal (n = 10)
-Did not attend appointment visit  (n = 26)
-Did not provide baseline swab sample (n = 1)
Included in primary analysis (n = 115)
Adhered to intervention (n = 113, 98%)
Included in primary analysis (n = 123)
Adhered to intervention (n = 114, 93%)
9–14 weeks
18–20 weeks 
Figure 1. Flow chart showing numbers of participants at each stage of the trial.
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retention ensured internal validity, while the multicentre
recruitment and broad inclusion criteria enhanced external
validity. We used probiotics that are safe during pregnancy
and have been reported to colonise the vagina in some
non-pregnant women within 2 weeks of treatment.19 Before
the start of the study, we confirmed the viability of the lac-
tobacilli in the probiotic capsules and that our laboratory
techniques would detect them in culture. Antibiotic pre-
scribing during pregnancy is common in the UK39 and we
took account of antibiotic exposure as a potential con-
founding variable. We did not take account of vaginal
douching, which may alter the vaginal microbiota with
adverse health consequences.40
The study has some limitations. The trial was underpow-
ered as a result of the lower than anticipated event rate, so
we can’t be certain of the magnitude of effect observed.
Secondly, we recruited and randomised fewer women than
planned, with only 23% (304/1031) of eligible women
agreeing to participate in the trial. The 2-month recruit-
ment phase of the trial was devised to estimate the feasibil-
ity of recruiting to a full-scale trial of oral probiotic
supplementation of women from early pregnancy to pre-
vent PTB. This response rate is, however, not unusual in
trials on apparently healthy participants who may not have
an expressed health need,41 particularly in pregnancy,
where there may be impediments to participation, mainly
due to perceived risk to the fetus.42 Thirdly, 77% (997/
1301) of eligible women were excluded from the trial
mainly due to refusal to participate. Fourthly, we had a
higher than expected number lost to follow up, which
tends to affect the ability to detect a difference. However,
as the direction of mean effect was opposite to that
hypothesised, our negative finding merits consideration.
Finally, adherence to the trial intervention, although over
90% in both groups, was reliant on self-reporting because
participants rarely remembered to bring in unused capsules
for a count at their scheduled antenatal visits. However, it
has been shown that self-reported compliance is a reliable
substitute for capsule count, particularly in trials where
there is regular in-person follow up.25
Comparison with other studies
Results of clinical trials in non-pregnant women have
reported positive effects of probiotics on BV.43 However,
Table 1. Baseline characteristics* and outcome at 18–20 weeks’
gestation of participants allocated to placebo or probiotics
Characteristic/Outcome Placebo group
(n = 152)
Mean (SD)
or n (%)
Probiotic
group (n = 152)
Mean (SD)
or n (%)
Maternal characteristics
Age (years) 31.3 (5.2) 31.1 (5.4)
Body mass index 25.1 (4.2) 25.4 (5.0)
Ethnicity
White 74 (48.7) 64 (42.1)
Black 18 (11.8) 27 (17.8)
Asian 51 (33.6) 50 (32.9)
Mixed/Other 9 (5.9) 11 (7.2)
Participant born preterm 6 (3.9) 6 (3.9)
Supplements/Medication use at baseline
Antibiotics 9 (5.9) 7 (4.6)
Other probiotics 3 (2.0) 6 (3.9)
Microbiological assessment at baseline
Bacterial vaginosis
(Nugent score ≥7)
18 (11.8) 27 (17.8)
Lactobacillus colonisation
reuteri 2 (1.3) 1 (0.7)
rhamnosus 6 (3.9) 5 (3.3)
Others 95 (62.5) 93 (61.2)
Escherichia coli 39 (25.7) 39 (25.7)
Group B Streptococcus 23 (15.1) 17 (11.2)
Placebo group
(n = 115)
Probiotic
group (n = 123)
Microbiological assessment at 18–20 weeks
Bacterial vaginosis
(Nugent score ≥7)**
10 (8.7) 19 (15.4)
Lactobacillus colonisation
reuteri 0 0
rhamnosus 6 (5.2) 6 (4.9)
Others 67 (58.3) 74 (60.2)
Escherichia coli 29 (25.2) 29 (23.6)
Group B Streptococcus 9 (7.8) 5 (4.1)
*There were no significant differences between the groups.
**P = 0.11.
0
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Figure 2. Mean Nugent scores with 95% confidence intervals from
9–14 to 34–36 weeks’ gestation of participants in the trial.
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Figure 3. Heat map showing the composition of the vaginal microbiota at baseline and at 18–20 weeks’ in placebo and probiotic groups.
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conclusive evidence has been hampered by inadequacies in
trial design (for example sample size), variations in the
interventions strains that were used, in the outcome mea-
sures, mode of administration, and control of confounding
factors such as use of antibiotics and topical antimicrobials.
Our findings support those recently reported by Gille
et al.44 In a randomised, controlled trial, 320 women at
<12 weeks’ gestational age were allocated to once-daily oral
capsules of L. rhamnosus GR-1 or L. reuteri RC-14 or pla-
cebo for 8 weeks. No differences were found in the preva-
lence of BV assessed by Nugent score between probiotic
and placebo groups before (placebo group 5.4% versus
probiotic group 2.8%, P = 0.376) and after the intervention
period (placebo group 1.5% versus probiotic group 2.2%,
P = 1.000).
Implications for clinical practice and research
The current study was part of a trial assessing the feasibility
of conducting a definitive trial on PTB prevention with
probiotics. PTB is the major determinant of adverse new-
born outcome. The rate of PTB is rising globally45 and cur-
rent strategies to stem its growth are ineffective.46 The
association between BV and PTB, and the reported benefits
of probiotic therapy on BV, mainly in non-pregnant
women, have raised interest in the role of probiotics in the
prevention of PTB.47 The observed benefit of dietary probi-
otic intake on the risk of spontaneous PTB48 supports this
concept. Although the probiotic supplements used in this
trial did not affect vaginal microbiota during pregnancy,
we believe that the notion of using probiotics to reduce the
risk of PTB merits further investigation. Future work
should first focus on identifying the probiotic strain(s) and
mode of administration that have a beneficial effect on the
vaginal microbiota during pregnancy before their role in
the prevention of PTB can be assessed.
Conclusion
Our study did not show evidence of an effect of oral probi-
otics on the vaginal microbiota in pregnancy.
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